Mark Dinubile is an Infectious Disease physician affiliated with Io Therapeutics. OpenAlex indexes 235 publications with 17,923 citations (h-index 54); ClinicalTrials.gov lists 3 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Infectious Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
505 Bartram Rd
Moorestown, NJ 080571833
Telephone
609-706-5866Registry record last updated 21 Jun 2014.
Clinical trials
- A Study to Evaluate Plasma Gelsolin in Healthy Volunteers
Sponsor: BioAegis Therapeutics Inc.
- Rhu-pGSN for Severe Covid-19 Pneumonia
Sponsor: BioAegis Therapeutics Inc.
- A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
Sponsor: BioAegis Therapeutics Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
New England Journal of Medicine
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Joseph Tauber, MD
Io Therapeutics
Michael Zinda, MD
Io Therapeutics
Khushboo Sheth, MB, BS
Io Therapeutics
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”